NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018

J Natl Compr Canc Netw. 2018 Nov;16(11):1289-1303. doi: 10.6004/jnccn.2018.0084.

Abstract

Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination / methods
  • Drug Therapy, Combination / standards
  • Hemorrhage / chemically induced
  • Hemorrhage / mortality
  • Hemorrhage / prevention & control*
  • Humans
  • Medical Oncology / methods
  • Medical Oncology / standards*
  • Medication Adherence
  • Neoplasms / complications*
  • Neoplasms / mortality
  • Patient Selection
  • Randomized Controlled Trials as Topic
  • Societies, Medical / standards
  • Survival Analysis
  • Time Factors
  • Treatment Outcome
  • United States
  • Venous Thromboembolism / diagnosis
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / mortality

Substances

  • Anticoagulants